A new immunotherapy drug has produced striking early results in men with advanced prostate cancer.Researchers reported tumour shrinkage and strong biological responses in some patients. Prostate cancer remains the most common cancer in men in many countries.About 1.5 million men receive a diagnosis worldwide each year. The treatment, called VIR-5500, activates the body’s own immune system.It links killer T-cells directly to cancer cells.This approach helps the immune system destroy tumours that usually evade detection. Scientists designed the…